Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:HEXO CVE:NRTH NASDAQ:VIR CVE:VM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHEXOHEXO$0.71+2.5%$0.87$0.66▼$3.84$31.24M1.35880,508 shs305,500 shsNRTH48North CannabisC$0.07-6.7%C$0.07C$0.07▼C$0.42C$15.76MN/A708,229 shs152,117 shsVIRVir Biotechnology$5.93+11.9%$5.17$4.32▼$14.45$732.66M1.221.36 million shs2.60 million shsVMVoyageur PharmaceuticalsC$0.26-10.3%C$0.21C$0.04▼C$0.36C$39.40M0.32198,469 shs345,648 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHEXOHEXO0.00%0.00%0.00%0.00%0.00%NRTH48North Cannabis0.00%0.00%0.00%0.00%0.00%VIRVir Biotechnology+11.89%+9.21%+9.21%+12.31%-29.15%VMVoyageur Pharmaceuticals-10.34%-16.13%+33.33%+33.33%+420.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHEXOHEXON/AN/AN/AN/AN/AN/AN/AN/ANRTH48North CannabisN/AN/AN/AN/AN/AN/AN/AN/AVIRVir Biotechnology3.1902 of 5 stars3.42.00.00.02.13.31.3VMVoyageur PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHEXOHEXO 0.00N/AN/AN/ANRTH48North Cannabis 0.00N/AN/AN/AVIRVir Biotechnology 2.86Moderate Buy$32.86454.08% UpsideVMVoyageur Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest NRTH, VM, HEXO, and VIR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025VIRVir BiotechnologyNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.005/12/2025VIRVir BiotechnologyNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$19.00 ➝ $14.004/17/2025VIRVir BiotechnologyThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$28.00 ➝ $21.00(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHEXOHEXO$146.20M0.21N/AN/A$2.44 per share0.29NRTH48North CannabisC$18.90M0.83C$0.01 per share8.75C$0.15 per share0.47VIRVir Biotechnology$74.21M11.05N/AN/A$8.35 per share0.71VMVoyageur PharmaceuticalsN/AN/AC$0.01 per share35.00C$0.01 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHEXOHEXO-$845.90M-$5.21N/AN/AN/A-235.33%-74.04%-32.51%N/ANRTH48North CannabisN/A-C$0.23N/A∞N/AN/AN/AN/AN/AVIRVir Biotechnology-$521.96M-$4.22N/AN/AN/A-2,769.04%-47.46%-39.33%7/30/2025 (Estimated)VMVoyageur Pharmaceuticals-C$1.66M-C$0.01N/A∞N/AN/A-117.77%-30.77%N/ALatest NRTH, VM, HEXO, and VIR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025VIRVir Biotechnology-$0.83N/AN/AN/AN/AN/A5/7/2025Q1 2025VIRVir Biotechnology-$0.83-$0.88-$0.05-$0.88$8.59 million$3.03 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHEXOHEXON/AN/AN/AN/AN/ANRTH48North CannabisN/AN/AN/AN/AN/AVIRVir BiotechnologyN/AN/AN/AN/AN/AVMVoyageur PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHEXOHEXO0.010.410.24NRTH48North Cannabis18.281.290.34VIRVir BiotechnologyN/A6.796.79VMVoyageur Pharmaceuticals4.230.100.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHEXOHEXO7.78%NRTH48North CannabisN/AVIRVir Biotechnology65.32%VMVoyageur PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipHEXOHEXO4.69%NRTH48North CannabisN/AVIRVir Biotechnology16.00%VMVoyageur Pharmaceuticals10.24%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHEXOHEXO1,27744.00 million41.93 millionOptionableNRTH48North Cannabis47225.17 millionN/ANot OptionableVIRVir Biotechnology580138.24 million116.12 millionOptionableVMVoyageur PharmaceuticalsN/A151.52 millionN/ANot OptionableNRTH, VM, HEXO, and VIR HeadlinesRecent News About These CompaniesVoyageur Pharmaceuticals (CVE:VM) Trading Down 11.5% - Here's WhyJuly 7 at 4:29 AM | americanbankingnews.comVoyageur Pharmaceuticals (CVE:VM) Shares Down 11.5% - Should You Sell?July 7 at 4:29 AM | americanbankingnews.comVoyageur Pharmaceuticals (CVE:VM) Stock Price Down 11.5% - Time to Sell?July 7 at 3:51 AM | americanbankingnews.comVoyageur Pharmaceuticals (CVE:VM) Trading Down 11.5% - Time to Sell?July 7 at 3:15 AM | americanbankingnews.comVoyageur Pharmaceuticals (CVE:VM) Stock Price Down 11.5% - Here's WhyJuly 7 at 2:35 AM | americanbankingnews.comVoyageur Pharmaceuticals (CVE:VM) Stock Price Down 11.5% - Should You Sell?July 7 at 2:49 AM | americanbankingnews.comVoyageur Pharmaceuticals (CVE:VM) Shares Down 11.5% - Here's WhyJuly 6, 2025 | americanbankingnews.comVoyageur Pharmaceuticals (CVE:VM) Stock Price Down 11.5% - What's Next?July 6, 2025 | americanbankingnews.comVoyageur Pharmaceuticals (CVE:VM) Trading Down 11.5% - Here's What HappenedJuly 6, 2025 | americanbankingnews.comVoyageur Pharmaceuticals (CVE:VM) Trading Down 11.5% - Should You Sell?July 6, 2025 | americanbankingnews.comVoyageur Pharmaceuticals (CVE:VM) Shares Down 11.5% - Here's What HappenedJuly 6, 2025 | americanbankingnews.comVoyageur Pharmaceuticals (CVE:VM) Stock Price Down 1.6% - Time to Sell?July 6, 2025 | americanbankingnews.comVoyageur Pharmaceuticals Ltd. (CVE:VM) Director Eugene Leonard Fritzel Acquires 32,250 SharesJuly 1, 2025 | insidertrades.comVoyageur Pharmaceuticals (CVE:VM) Trading 21.8% Higher - Here's WhyJune 27, 2025 | marketbeat.comVoyageur Pharmaceuticals (CVE:VM) Shares Up 20% - Here's What HappenedJune 27, 2025 | marketbeat.comVoyageur Pharmaceuticals (CVE:VM) Stock Price Up 21.8% - Should You Buy?June 27, 2025 | marketbeat.comVoyageur Pharmaceuticals (CVE:VM) Shares Up 23.6% - Time to Buy?June 27, 2025 | marketbeat.comVoyageur Pharmaceuticals (CVE:VM) Stock Price Up 20% - Should You Buy?June 27, 2025 | marketbeat.comVoyageur Pharmaceuticals (CVE:VM) Trading 12.7% Higher - Here's WhyJune 27, 2025 | marketbeat.comVoyageur Pharmaceuticals Launches First Commercial Sale of Barium Contrast AgentsJune 4, 2025 | msn.comVoyageur Launches Market Introduction of Barium Contrast Product Line Following Successful Clinical Study ResultsApril 24, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBroadcom’s Big VMware Update: A Threat to Public Cloud Giants?By Leo Miller | June 28, 2025View Broadcom’s Big VMware Update: A Threat to Public Cloud Giants?NRTH, VM, HEXO, and VIR Company DescriptionsHEXO NYSE:HEXOHEXO Corp., together with its subsidiaries, produces, markets, and sells cannabis in Canada. The company offers its adult-use and medical products under the HEXO brand name. It also provides cannabis beverages under the Little Victory, House of Terpenes, Mollo, Veryvell, and XMG brands; and cannabis products under UP Cannabis, Original Stash, and Up brand names. It has a strategic alliance with Tilray Brands, Inc. The company was formerly known as The Hydropothecary Corporation and changed its name to HEXO Corp. in August 2018. HEXO Corp. was founded in 2013 and is headquartered in Gatineau, Canada. As of June 22, 2023, HEXO Corp. operates as a subsidiary of Tilray Brands, Inc.48North Cannabis CVE:NRTHC$0.07 -0.01 (-6.67%) As of 09/2/202148North Cannabis Corp. operates as a cannabis company in the health and wellness market in Canada. The company offers bath salts, intimacy oils, flowers, pre-rolls, body cream and oil, vapes, pressed hash, and accessories under 48North, Apothecanna, First Harvest, Avitas, F8, Trail Mix, and Latitude brands. It also provides LAT, a publication and creative platform that empowers women to connect, engage, and learn through their experiences with cannabis. 48North Cannabis Corp. is headquartered in Toronto, Canada.Vir Biotechnology NASDAQ:VIR$5.93 +0.63 (+11.89%) Closing price 07/9/2025 04:00 PM EasternExtended Trading$5.95 +0.02 (+0.34%) As of 07/9/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.Voyageur Pharmaceuticals CVE:VMC$0.26 -0.03 (-10.34%) As of 07/9/2025 04:34 PM EasternVoyageur Pharmaceuticals Ltd., together with its subsidiaries, engages in the acquiring, exploring, and developing raw materials for pharmaceutical products, primarily in the province of British Columbia, Canada, and the state of Utah. The company develops barium and iodine-based APIs. The company was formerly known as Voyageur Minerals Ltd. and changed its name to Voyageur Pharmaceuticals Ltd. in December 2019. Voyageur Pharmaceuticals Ltd. was founded in 2017 and is headquartered in Calgary, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Why Marvell Could Be the Smartest AI Bet Under $80 Autodesk Stock Ready to Rip? Q3 May Be the Turning Point Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Palantir’s Revenue Surge to $1B: Growth vs. Valuation Chime Financial: Analysts Ring In—And It’s a Buy Is Fortinet Ready to Break Out After Months of Consolidation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
